Hims & Hers Health, Inc. (HIMS) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $26.90: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 33%; Elevated put/call ratio: 1.97; Below-average business quality.
Hims & Hers is a US-led telehealth and digital health platform offering subscription-based prescription and non-prescription treatments for sexual health, hair loss, weight loss, dermatology, and mental health. Revenue grew from $872M (2023) to $2,347.6M (2025), driven primarily... Read more
Sell if holding. Engine safety override at $26.90: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 33%; Elevated put/call ratio: 1.97; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 61. Score 4.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Hims & Hers Health, Inc.
Latest news
- NEWS Stocks Under $50 to Buy or Avoid in May 2026: Hims & Hers, Insteel, Helix Energy - News and Statistics - IndexBox — IndexBox neutral
- NEWS Hims & Hers Health, Inc. (HIMS) stock drops despite market gains: Important facts to note - MSN — MSN negative
- NEWS Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance — Yahoo Finance negative
- NEWS HIMS Stock | Hims & Hers Health Price, Quote, News & Analysis - TipRanks — TipRanks neutral
- NEWS Hims & Hers Expands DTC Platform to Broaden Access to Personal Care - The Globe and Mail — The Globe and Mail positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Volatile — 8.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -0.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.90: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 33%; Elevated put/call ratio: 1.97; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $24.94. Score 4.2/10, moderate confidence.
Take-profit target: $29.22 (+8.9% upside). Prior stop was $24.94. Stop-loss: $24.94.
Target reached (-13.7% upside); Quality below floor (3.8 < 4.0).
Hims & Hers Health, Inc. trades at a P/E of N/A (forward 30.1). TrendMatrix value score: 5.7/10. Verdict: Sell.
23 analysts cover HIMS with a consensus score of 3.5/5. Average price target: $27.
What does Hims & Hers Health, Inc. do?Hims & Hers is a US-led telehealth and digital health platform offering subscription-based prescription and...
Hims & Hers is a US-led telehealth and digital health platform offering subscription-based prescription and non-prescription treatments for sexual health, hair loss, weight loss, dermatology, and mental health. Revenue grew from $872M (2023) to $2,347.6M (2025), driven primarily by US subscription-based prescription products fulfilled through company-owned pharmacies and partner pharmacies. The company faces regulatory risk around GLP-1 compounded semaglutide.